Focused on Diagnostic Imaging
Rio Pharmaceuticals, a Delaware company, aims to transform the diagnosis of neurological diseases through the development of a new PET imaging tool that can detect pathological changes in the human brain. We believe that the specific pattern of changes detected by our reagent will serve as a kind of fingerprint that should provide clinicians with an unambiguous diagnosis.
What is PET?
PET is a way to obtain quantitative neurochemical data from a living being. PET uses radioactive molecules with a high affinity for a specific protein in the body. A small amount of the compound is injected into the body, and then, radioactive decay events are recorded with a special camera. The location of the decay event is then mapped onto the tissue location. In this way, the density of the target protein at a given anatomic location can be inferred by the events recorded by the camera.
